A human inhibitor of tumor necrosis factor alpha by unknown
A HUMAN INHIBITOR OF TUMOR NECROSIS FACTOR a
By PHILIPPE SECKINGER, SYLVIA ISAAZ, AND JEAN-MICHEL DRYER
From the Division of Immunology and Allergy (Hans Wilsdorf Laboratory), Department of
Medicine, University Hospital, 1211 Geneva 4, Switzerland
TNF is a protein identified by its ability to induce cytotoxicity for tumor cells
and to inhibit their growth in culture (1). TNF-a (also termed cachectin), mainly
produced by monocytes/macrophages, mediates and participates in a wide range
of biological activities (2, 3) . In addition, TNF-a shares several of its activities
with IL-1, among them prostaglandin E2 (PGE2) and collagenase production by
human dermal fibroblasts and synovial cells (4) . Both IL-1 and TNF-a induce
fever by stimulating hypothalamic PGE2 synthesis (5) .
To our knowledge, no inhibitory factor directed against TNF activity has been
reported yet. We previously isolated a specific IL-1 inhibitor from the urine of
febrile patients (6-8). As TNF and IL-1 are both mediators of fever, we won-
dered whether such urine might also contain a TNF-a inhibitory (TNF-a INH)
activity. Indeed, we found an inhibitory factor of 40-60 kD, therefore proving
the existence, as in the case of IL-1, of at least one negative feedback regulator.
Volume 167 April 1988 1511-1516
Materials and Methods
BriefDefinitive Report
Urine Collection.
￿
Urine (15 liters) was freshly obtained before any treatment from a
pool of five patients, two of whom were suffering from small-cell carcinoma, one from
malignant histiocytosis, one from polymyositis, and one from sepsis. All patients were
highly febrile (>38.5°C) and devoid of urinary infections. Urine was concentrated and
ammonium sulfate precipitated as described earlier (6-8).
Reagents and Media.
￿
PBS, MEM, FCS, penicillin, streptomycin, and glutamine were
obtained from Gibco (Paisley, Scotland). Human rTNF-a (hrTNF-a) was produced in
Escherichia coli at Biogen S. H ., Geneva, Switzerland.
Bioassay of TNF-a INH.
￿
TNF-a INH activity was measured in an assay of cytotoxicity
using a TNF-susceptible cell line L929, as previously described (9).
Quantitation of TNF-a INHActivitiy.
￿
The percentage of TNF-a INH was determined
by assuming that OD values from cells stimulated by actinomycin D corresponded to
100% of inhibition, whereas OD from cells cultured with actinomycin D and hrTNF-a
corresponded to maximal cell mortality of 0% of TNF-a INH. The percentage of TNF-
a INH in the assay of cytotoxicity was calculated by the following formula: Percentage
of TNF-a INH = 100 X f[(OD with actinomycin D + hrTNF-a + TNF INH) - (OD
with actinomycin D + hrTNF-a)]/[(OD with actinomycin D) - (OD with actinomycin D
+ hrTNF-a)])
Molecular Sieve Chromatography. All dialysis and chromatographic steps were per-
formed at 4°C. Gel filtration chromatography was carried out on a Sephacryl S-200 col-
umn (0.9 X 60 cm) (Pharmacia Fine Chemicals, Uppsala, Sweden), equilibrated in 50
mM Tris-HCI buffer, pH 7.4, containing 100 mM NaCl. 20 mg of protein was applied
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(0.8 ml) to the column and eluted with the same buffer at a flow rate of 5 .4 ml/h. Frac-
tions (1 .35 ml) were collected and tested for TNF-a INH activity.
FPLC Chromatofocusing.
￿
Chromatofocusing was performed with a Mono P prepacked
column (HR 5/20, 5 X 200 mm; Pharmacia Fine Chemicals) equilibrated in 25 mM Bis-
Tris buffer adjusted to pH 7.1 with iminodiacetic acid (Fluka, Buchs, Switzerland). 30
mg of protein was applied to the column and eluted with a polybuffer 74/iminodiacetic
acid at pH 4.0. The actual pH of each fraction (1 ml) was determined with a pH meter,
and TNF-a INH inactivity was evaluated.
Trypsin Digestion.
￿
50 Ecl of trypsin (10 mg/ml) (Sigma Chemical Co., St. Louis, MO)
in 0.2 M Tris-HCl buffer, pH 8.0, containing 1 mM calcium chloride was added to 500
A1 of Sephacryl S-200 semipurified urine dialyzed against the above-mentioned buffer.
After 4 h of incubation at 37°C, a second 50-Al sample of trypsin was added to the diges-
tion mixture. The reaction was terminated after 24 h by adding 100 1l soybean trypsin
inhibitor (20 mg/ml) (Sigma Chemical Co.). Trypsin digest and controls were tested at a
1 :20 final dilution on L929 cells and in the presence of hrTNF-a at 0.2 ng/ml
concentration.
Results
Identification of a Urine-derived TNF-a INH Activity.
￿
Amicon-concentrated
and ammonium sulfate-precipitated urine (40-80%) showed TNF-a INH activ-
ity when tested in a cytotoxicity assay with the TNF-susceptible cell line L929 in
the presence of actinomycin D. Thus, at a 1 :20 final urine dilution, total inhib-
ition of the cytotoxic effect induced by hrTNF-a was observed so that OD570
value was identical to that measured in the presence of actinomycin D alone
(OD570 = 1 .5). Moreover, this material showed inhibitory activity in urine dilu-
tions of up to 1 :160 on cells (OD570 = 0.83) whereas control value of hrTNF-
a at a final concentration of 0 .2 ng/ml measured in the presence of actinomycin
D was lower (013570 = 0.73), so that 50% of inhibition was observed at a dilution
of ^-1 :100 (013570 - 1 .10) . The TNF-a INH had no effect on cell viability when
tested without actinomycin D (data not shown) .
Characterization of the Urinary TNF-a INH.
￿
Salt-precipitated urine was sub-
jected to Sephacryl S-200 gel filtration. The inhibitory activity was eluted from
the gel in a single peak and maximal inhibitory activity showed an apparent
molecular mass of 40-60 kD (Fig. 1) . In another experiment, the salt-precipi-
tated urine was chromatofocused on a Mono-P HR 5/20 column as described
in Materials and Methods. Fig. 2 shows that eluted fractions between pH 5.5
and 6 .1 contained the bulk of TNF-a INH activity.
Experiments were performed to establish whether the TNF-a INH activity was
due to a protein. Heating of Sephacryl S-200 semi-purified TNF-a INH at 56,
75, and 95°C reduced its activity in a time- and temperature-dependent fashion
(Table I) . In another experiment, trypsin digestion for 24 h at 37°C reduced the
inhibitory activity by -60% (Table I). The possibility still remained that a mol-
ecule of low molecular weight binding to a protein was the active moiety of the
inhibitory activity. Consequently, 1 ml of Sephacryl S-200 fraction was adjusted
to 2 M urea and extensively dialyzed at 4°C against PBS containing 2 M urea.
This material was dialyzed against PBS again before the bioassay; the inhibitory
activity was found to be unaffected (data not shown) .
We next investigated whether an excess of TNF-a was capable of overcoming
the effect of the inhibitor. A consistent amount (25 gl) of Sephacryl S-200E c
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Fraction number
FIGURE 1 .
￿
Urinary TNF-a INH activity profile of Sephacryl S-200 gel filtration. Urine of
febrile patients was concentrated, ammonium sulfate-precipitated, and passed through
molecular sieve chromatography as described in Materials and Methods. Column fractions
were tested at 1:10 dilution for effect in the hrTNF-a (1 .0 ng/ml) cytotoxicity assay in the
presence of actinomycin D (1 ug/ml) (o). Bars represent cell lysis measured by dye uptake at
570 nm in response to actinomycin D(E)) and to actinomycin D plus hrTNF-a (O)without
urine. Molecular weight markers are dextran blue (DB); BSA; OVA; a-chymotrypsinogen-A
(aCT); RNase, and phenol-red ((h-red).
Fraction number
FIGURE 2.
￿
Urinary TNF-a INH activity profile of chromatofocusing Mono P column. Urine
of febrile patients was concentrated, ammonium sulfate precipitated, and chromatofocussed
as described in Materialsand Methods. Column fractions (1 .0 ml)were tested at 1:10 dilution
for the effect in hrTNF-a (0.2 ng/ml) cytotoxicity assay in the presence of actinomycin D (1
jug/ml) (o). Bars represent cell lysis measured by dye uptake at 570 nm in response to acti-
nomycin D(p)and to actinomycin D plus hrTNF-a(m)without urine samples.
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*Urine, partially purified by Sephacryl S-200, was heat inactivated at temperatures and times indi-
cated. Remaining TNF-a activity was compared to untreated samples. Percentage of TNF-a INH
activity was determined by using the formula reported in Materials and Methods. When exposing
cells to actinomycin D alone (1 P,g/ml)and to actinomycin D + hrTNF-a (0.2 ng/ml), OD570values
were 1.49 and 0.06, respectively.
I Urine, partially purified by Sephacryl S-200, was digested with trypsinas describedin Materialsand
Methods. Conditions (1 :20 dilution) represent buffer in the absence and presence of trypsin and
soybean trypsin inhibitor (SBTI), as well as urine in the absence or presence of trypsin, followed by
inactivation with SBTL Values indicate the percentage of inhibition on hrTNF-a (0.2 ng/ml) -
inducedcytotoxicity in thepresence of actinomycin D (1 jAg/ml). When exposing cellsto actinomycin
D (1 ug/ml) alone and to actinomycin D + hrTNF-a (0.2 ng/ml), OD570 were 0.90 and 0.76,
respectively.
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TABLE I
Biochemical Characterization of TNF-a INH
Inactivation treatmentof TNF-aINH activity
0
FIGURE 3. Reversibility of
TNF-a INH activity. Partially
purified Sephacryl S-200
urine was tested at a 1 :10
dilution against increasing
amounts of hrTNF-aon L929
cells. The bar represents cell
lysis measured by dye uptake
at 570 nm in response to acti-
nomycin D (1 /g/ml) alone.
(o) OD measured in the pres-
ence of actinomycin D, an
appropriate amount of TNF-
a INH and increasing
amounts of hrTNF-a. (0) OD
in the presence of actinomy-
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Heat
Temperature
inactivation*
Time TNF-a INH
activity
Trypsin
Conditions
inactivation2
TNF-a INH
activity OD570
min % %
10 100 Buffer alone 0 0.71
56°C 20 100
60 93 Trypsin + soybean
trypsin inhibitor 0 0.70
10 60 in buffer
75°C 20 26 Partially purified
60 15 Sephadex S-200 61 1.46
urine
10 27 Partially purified
95°C 20 10 Sephadex S-200 23 1.03
60 13 urine digested by
trypsinSECKINGER ET AL.
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semipurified inhibitor (equivalent to 1 :10 final dilution on cells) was added to
increasing amounts of hrTNF-a. As shown in Fig. 3, there was an inverse cor-
relation between the amount of hrTNF-a present in the assay and the degree of
inhibition observed. Thus, the inhibitory activity was competitively overcome by
increasing concentrations of hrTNF-a.
Discussion
We have found that when tested in a cytotoxicity assay, urine from febrile
patients contained a TNF-a inhibitory activity whose nature remains to be deter-
mined by purification to homogeneity, many bands being still identified in SDS-
PAGE of the Sephacryl S-200 inhibitory fractions. Purification will enable us to
establish a relationship with one or more other putative inhibitors . Thus, uro-
modulin, which binds TNF as well as IL-1, had no inhibitory activity when tested
in our cytotoxicity assay, even at final concentrations as high as 2 ug/ml. Primary
characterization indicates that the inhibitory activity is due to a protein, as it is
sensitive to trypsin and pronase, with a pI ranging from 6.1 to 5.5 and an appar-
ent mol wt of 40-60 X 103. This argues against the hypothesis that denatured
TNF is responsible for the TNF-a INH activity by displacing the active native
TNF-a from its receptor. Using a Western blotting technique, after a run of the
semipurified Sephadex S-200 inhibitory fraction on SDS-PAGE under reducing
conditions, no reactivity for any mol wt <26 X 103 was seen with polyclonal
goat antisera raised against hrTNF-a (a gift from R. V. Ulevitch, Scripps Clinic) .
Thus, neither a TNF-a precursor nor denatured TNF seems to be responsible
for TNF-a INH activity. The TNF-a INH activity shows heat sensitivity, whereas
it is fully maintained after urea treatment, eliminating the possibility that a small
molecule is responsible for the TNF-a inhibition.
The results indicate that the inhibitor is specific for TNF-a and not due to an
actinomycin D binding protein, as TNF-a INH activity was entirely overcome by
increasing TNF-a concentrations without changing that of actinomycin D. Our
data suggest a competitive mechanism of action perhaps situated at the receptor
level itself, as is the case with the IL-1 INH previously observed in urine of
similar patients (7, 8, 10). It should be emphasized that urine from some febrile
patients seems to be an important source of either IL-1 or TNF-a inhibitory
activities and that, in analogy to the IL-1 INH, the relationship between TNF-a
INH or IL-1 INH activities and disease still remains to be investigated. The
question as to whether the present TNF-a INH is also effective against other
bioactivities induced by TNF-a has already been approached, and it has been
shown that the PGE2 production induced by TNF-a on human fibroblasts may
well be inhibited by the present TNF-a INH (manuscript in preparation), which
means that it is also effective on non-actinomycin D-treated cells. The present
TNF-a INH differs unequivocally from the IL-1 inhibitor, since the latter did
not inhibit TNF-a-induced cytotoxicity to murine L929 cells. Moreover, the
TNF-a INH shows a higher molecular weight and does not inhibit the binding
of ' 25I-IL-la to the murine thymoma subline EL4-6.1 . Like the IL-1 INH, the
TNF-a INH is a nonspecies-specific inhibitor as it acts on a murine cell line .151 6
￿
SECKINGER ET AL.
￿
BRIEF DEFINITIVE REPORT
Summary
Urine of some febrile patients exibits a TNF-a inhibitory activity (TNF-a
INH), sensitive to heat and trypsin, with an apparent mol wt of 40-60 X 103
and a pl range of 5.5-6 .1 . As for the Il-1 INH, the TNF INH activity involves
a competitive mechanism of action suggesting the existence of a family of neg-
egulating molecules interfering with cytokines actions.
The authors wish to thank A. Rohner for providing hepatic tissue; P. Moonen (Biogen
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